- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01775436
Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care (FACE)
Our goal is to advance palliative care with persons living with AIDS (PLWA) or life-limiting co-morbidities to decrease suffering and increase quality of life (QOL). Left without advance care planning (ACP) for end-of-life decision, miscommunication and disagreements may result in families being charged with neglect or court battles over treatment choices, unmet care or delivery of unnecessary or unwanted care, and non-relative caregivers being dismissed (e.g. gay partners). We hope to increase families' understandings of their family member's wishes for end-of-life care to decrease conflict through the FAmily-CEntered Advance (FACE) Care Planning intervention. We will also study communication, quality of life, and spiritual struggle. Families will be randomized into either the Control (N=96 families) or the FACE Intervention (n=192 dyads). FACE families will meet with a trained/certified researcher for two 60-minute sessions scheduled one week apart: Session 1: The Respecting Choices Interview®; and Session 2: Completion of The Five Wishes©. Control families will also meet with a researcher for two 60-minute sessions scheduled one week apart: Session 1: Developmental History; and Session 2: Nutrition and Exercise. Questionnaires will be administered five times, Baseline and at 3, 6, 12 and 18 month post-intervention, for an average of 2 years.
AIM 1. To determine the efficacy of FACE on congruence in treatment preferences between PLWA and their surrogates over time, and the effect of the pattern of congruence development trajectory on healthcare utilization (i.e., distal outcomes: number of hospitalizations, dialysis, ER visits).
Hypothesis A: Development of congruence may not be homogeneous and FACE may influence the pattern of congruence development.
Hypothesis B: Different patterns of congruence development may have different effects on health care utilization.
Hypothesis C: Compared to Controls, FACE participants will better maintain congruence over time.
AIM 2. To determine the efficacy of FACE on key components of QOL for PLWA. Hypothesis: FACE participants will increase or better maintain psychosocial QOL compared to Controls.
AIM 3. To minimize health disparities in ACP between Blacks and non Blacks and identify factors associated with disparities.
Hypothesis: Blacks in the FACE intervention will complete advance directives at a rate comparable to non Blacks, and at significantly greater rates compared to Controls.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
District of Columbia
-
Washington, District of Columbia, Stany Zjednoczone, 20010
- Children's National Medical Center
-
Washington, District of Columbia, Stany Zjednoczone, 20037
- George Washington University
-
Washington, District of Columbia, Stany Zjednoczone, 20007
- Georgetown University Hospital
-
Washington, District of Columbia, Stany Zjednoczone, 20010
- Institute for Clinical Research, Inc. (Affiliated with Department of Veterans Affairs Medical Center of Washington, DC)
-
Washington, District of Columbia, Stany Zjednoczone, 20010
- MedStar Health Research Institute/Washington Hospital Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Patient Inclusion Criteria:
- HIV positive outpatients or inpatients with detectable viral load (>200 copies) twice in the past 1 year period OR CD4 count <200 OR with a co-morbidity that may significantly limit life expectancy, including malignancy, cirrhosis, cardiomyopathy, etc.
- Patients with AIDS receiving dialysis, inpatients or outpatients
- Patients not in the Intensive Care Unit (ICU)
- Age 21 years or older
- All ethnic groups
- Male or female
- Knows his/her HIV status
- English speaking
- Absence of active psychosis or homicidal or suicidal ideation, determined at baseline screening by a trained research assistant as assessed by questions from a structured questionnaire
- Absence of HIV dementia, determined at screening using the HIV Dementia Scale cut off score of <10
- No evidence of developmental delay
- Consent from surrogate
- Consent from persons living with AIDS (PLWA) aged 21 or older
Surrogate Decision-maker inclusion criteria:
- Selected by patient
- Age 18 or older
- Willingness to discuss problems related to HIV and End Of Life (EOL)
- Absence of active psychosis, homicidal ideation, or suicidal ideation determined at baseline screening by trained RA
- Absence of HIV dementia, determined at screening using the HIV Dementia Scale cut off score of <10
- English speaking
- Consent to participate
- Knows HIV status of patient
Patient Exclusion Criteria:
- Patients in the ICU
- Age under 21 years old
- Patient unaware of HIV status
- Active psychosis or homicidal or suicidal ideation, determined at baseline screening by a trained research assistant as assessed by questions from a structured questionnaire
- Presence fo HIV Dementia at baseline
- Developmental delay
- Unable to find willing consented surrogate
Surrogate Decision-maker Exclusion Criteria:
- Surrogate under age of 18 years old
- Unwilling to discuss problems related to HIV and EOL
- Active psychosis or homicidal or suicidal ideation, determined at baseline screening by a trained research assistant as assessed by questions from a structured questionnaire
- Not an English speaker
- Unwilling to consent to participate and does not know HIV status of patient
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Aktywny komparator: Healthy Living Control
Two-60 to 90 minute sessions scheduled one week apart. Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention. |
Two-60 to 90 minute sessions scheduled one week apart. Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes. Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.
Inne nazwy:
Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
Inne nazwy:
|
Eksperymentalny: FAmily-CEntered Advance Care Planning
Two-60 to 90 minute sessions scheduled one week apart. Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes. Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have. |
Two-60 to 90 minute sessions scheduled one week apart. Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes. Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.
Inne nazwy:
Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Statement of Treatment Preferences
Ramy czasowe: Baseline and 3, 6, 12, 18 month post-intervention
|
Measured by the Statement of Treatment Preferences.
This measure was adapted using experts and community advisory board.
It is a tool to express values and goals related to future medical decisions regarding frequently occurring situations specific to HIV/AIDS.Multiple Time Frames are needed as the Primary Outcome measure is going to report a change over time, per Aim 1: "to sustain congruence in treatment preferences between PLWA and their surrogate over time" compared to controls.
|
Baseline and 3, 6, 12, 18 month post-intervention
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Lyon Advance Care Planning Survey (Patient and Surrogate Version)
Ramy czasowe: at baseline
|
A 31-item instrument that assesses palliative care needs of PLWA of Black and non Black PLWA in DC metropolitan area
|
at baseline
|
Palliative Care Outcome Scale (POS)
Ramy czasowe: Baseline, and 3, 6, 12 and 18 month post-intervention
|
This scale is a valid and reliable measure of patient's current health, social and psychological status.We are conducting a longitudinal study and therefore looking at multiple time frames for change in palliative care over time.
|
Baseline, and 3, 6, 12 and 18 month post-intervention
|
Medical Outcomes Study-HIV (MOS-HIV)
Ramy czasowe: Baseline, and 3, 6, 12 and 18 month post-intervention
|
Measures HIV specific Health Related Quality of Life; general health perceptions; pain; physical, role, cognitive and social functioning; mental health; energy/fatigue; health distress and quality of life.
This is a longitudinal study requiring multiple time frames so we can report change in quality of life over time, related to HIV specific symptoms.
|
Baseline, and 3, 6, 12 and 18 month post-intervention
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
HIV Dementia Scale
Ramy czasowe: Screen for eligibility at Baseline, 3, 6, 12 and 18 months post intervention
|
Rapid screener to identify HIV dementia, which is an exclusion criteria.
However, once enrolled in the study we will track changes in status over time, per the longitudinal nature of this study.
|
Screen for eligibility at Baseline, 3, 6, 12 and 18 months post intervention
|
Psychological Interview
Ramy czasowe: Baseline to screen to determine eligibility
|
Questions to screen for homicidality and psychosis
|
Baseline to screen to determine eligibility
|
Patient Health Questionnaire (PHQ-9)
Ramy czasowe: Baseline screening to determine if eligible for participation, then at 3, 6, 12 and 18 month post-intervention follow-up
|
Patients or surrogates who present with severe depression or suicidality are excluded from this study.
However, once enrolled levels of depressive symptoms will be monitored over the course of this longitudinal study.
|
Baseline screening to determine if eligible for participation, then at 3, 6, 12 and 18 month post-intervention follow-up
|
Medication Adherence Self Report Inventory (MASRI)
Ramy czasowe: Baseline and 3, 6, 12 and 18 month follow-up
|
Validated self-report measure of medication adherence, using the Visual Analogue Scale for estimated adherence in the past month.
Measured multiple times as part of this longitudinal study.
|
Baseline and 3, 6, 12 and 18 month follow-up
|
Brief Multidimensional Measurement of Religiousness/Spirituality (BMMRS-adapted)
Ramy czasowe: Baseline and 3, 6, 12 and 18-month post intervention
|
Assesses the construct of spiritual functioning, specifically subscales for Forgiveness, Values and Believes will be used for study purposes.
|
Baseline and 3, 6, 12 and 18-month post intervention
|
Brief Religious Coping Questionnaire (Brief RCOPE)
Ramy czasowe: Baseline and 3, 6, 12 and 18-month post-intervention
|
Assesses positive and negative religious coping methods.
Study will use 14-item version.
|
Baseline and 3, 6, 12 and 18-month post-intervention
|
Satisfaction Scale
Ramy czasowe: Immediately following Session 1 and Session 2, week 2 and week 3 of the study
|
Process measure developed in pilot study to assess satisfaction.
|
Immediately following Session 1 and Session 2, week 2 and week 3 of the study
|
Longitudinal Satisfaction Questionnaire
Ramy czasowe: 3, 6, 12 and 18 month post-intervention
|
Process measure to assess longitudinal satisfaction with future decision making.
|
3, 6, 12 and 18 month post-intervention
|
Medical Chart Abstraction
Ramy czasowe: Baseline and 3, 6, 12 and 18 month post intervention
|
Mode of transmission, Cluster of Differentiation 4 (CD4) count, viral load, hospitalization, emergency room visit or dialysis since last study visit.
|
Baseline and 3, 6, 12 and 18 month post intervention
|
Threat Appraisal Scale (TAS)
Ramy czasowe: Baseline, 3, 6, 12 and 18 month post-intervention
|
Threat Appraisal Scale (TAS)is a questionnaire administered to the adolescent during baseline assessment only.
This measure will retrospectively estimate the adolescent's threat appraisal of cancer when adolescent learned of cancer diagnosis.
Test-retest reliability for this measure ranges from .68 in younger children to .93 in older children.
TAS scores are found to demonstrate a high degree of agreement with children's open-ended descriptions of negative life events, indicating adequate convergent validity of this measure.
Theoretically, threat appraisal is related to Lazarus' concept of primary appraisal, particularly to the way in which the event threatens the child's commitments, goals, or values.
Higher threat appraisals should lead to negative arousal and coping and to increased psychological symptoms.
|
Baseline, 3, 6, 12 and 18 month post-intervention
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Maureen E Lyon, PhD, Children's National Research Institute
Publikacje i pomocne linki
Publikacje ogólne
- Kimmel AL, Wang J, Scott RK, Briggs L, Lyon ME. FAmily CEntered (FACE) advance care planning: Study design and methods for a patient-centered communication and decision-making intervention for patients with HIV/AIDS and their surrogate decision-makers. Contemp Clin Trials. 2015 Jul;43:172-8. doi: 10.1016/j.cct.2015.06.003. Epub 2015 Jun 2.
- Lyon ME, Squires L, D'Angelo LJ, Benator D, Scott RK, Greenberg IH, Tanjutco P, Turner MM, Weixel TE, Cheng YI, Wang J. FAmily-CEntered (FACE) Advance Care Planning Among African-American and Non-African-American Adults Living With HIV in Washington, DC: A Randomized Controlled Trial to Increase Documentation and Health Equity. J Pain Symptom Manage. 2019 Mar;57(3):607-616. doi: 10.1016/j.jpainsymman.2018.11.014. Epub 2018 Nov 23.
- Curtin KB, Cheng YI, Wang J, Scott RK, Squires L, Benator DA, Lyon ME; Palliative Care Consortiums. Quality of life of persons living with HIV and congruence with surrogate decision-makers. Qual Life Res. 2019 Jan;28(1):47-56. doi: 10.1007/s11136-018-2002-5. Epub 2018 Sep 15.
- Lyon ME, Squires L, Scott RK, Benator D, Briggs L, Greenberg I, D'Angelo LJ, Cheng YI, Wang J. Effect of FAmily CEntered (FACE(R)) Advance Care Planning on Longitudinal Congruence in End-of-Life Treatment Preferences: A Randomized Clinical Trial. AIDS Behav. 2020 Dec;24(12):3359-3375. doi: 10.1007/s10461-020-02909-y.
- Grill KB, Wang J, Cheng YI, Lyon ME. The Role of Religiousness and Spirituality in Health-related Quality of Life of Persons Living with HIV: A Latent Class Analysis. Psycholog Relig Spiritual. 2020 Nov;12(4):494-504. doi: 10.1037/rel0000301. Epub 2020 Jan 30.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
- opieka paliatywna
- jakość życia
- Komunikacja
- przyczepność
- dializa
- hospitalizacja
- HIV/AIDS
- podejmowanie decyzji
- planowanie opieki z wyprzedzeniem
- koniec życia
- interwencja rodziny
- duchowy
- kongruencja leczenia
- preferencje dotyczące leczenia
- ocena zagrożenia
- Planowanie zaawansowanej opieki zorientowanej na rodzinę
Dodatkowe istotne warunki MeSH
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby przenoszone drogą płciową, wirusowe
- Choroby przenoszone drogą płciową
- Infekcje lentiwirusowe
- Zakażenia Retroviridae
- Zespoły niedoboru odporności
- Choroby układu odpornościowego
- Powolne choroby wirusowe
- Zakażenia wirusem HIV
- Zespół nabytego niedoboru odporności
Inne numery identyfikacyjne badania
- 1R01NR01405201
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Ramy czasowe udostępniania IPD
Kryteria dostępu do udostępniania IPD
Researchers or graduate students in need of a master's theses or dissertation project from academic settings, e.g. university or academic/research hospital will be allowed to have access to de-identified data.
Contact the PI Dr. Lyon at mlyon@childrensnational.org.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutacyjnyHIV | Test na HIV | Związek HIV z opieką | Leczenie HIVStany Zjednoczone
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement i inni współpracownicyNieznanyHIV | Dzieci niezakażone wirusem HIV | Dzieci narażone na HIVKamerun
-
University of MinnesotaWycofaneZakażenia wirusem HIV | HIV/AIDS | HIV | AIDS | Problem z AIDS/HIV | AIDS i infekcjeStany Zjednoczone
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationZakończonyPartnerskie testy na obecność wirusa HIV | Porady dotyczące HIV dla par | Komunikacja pary | Zapadalność na HIVKamerun, Republika Dominikany, Gruzja, Indie
-
Hospital Clinic of BarcelonaZakończonyInhibitory integrazy, HIV; INHIB PROTEAZY HIVHiszpania
-
University of Maryland, BaltimoreWycofaneHIV | Przeszczep nerki | Zbiornik HIV | CCR5Stany Zjednoczone
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... i inni współpracownicyRekrutacyjnyHIV | Test na HIV | Połączenie z opiekąAfryka Południowa
-
CDC FoundationGilead SciencesNieznanyProfilaktyka przed ekspozycją na HIV | Chemioprofilaktyka HIVStany Zjednoczone
-
Erasmus Medical CenterJeszcze nie rekrutacjaZakażenia wirusem HIV | HIV | Zakażenie HIV-1 | Zakażenie wirusem HIV IHolandia
-
Helios SaludViiV HealthcareNieznanyHIV | Zakażenie HIV-1Argentyna
Badania kliniczne na FAmily-CEntered Advance Care Planning
-
University of GiessenUniversity of UlmRekrutacyjnyOpieka skoncentrowana na rodzinieNiemcy
-
Chung Shan Medical UniversityZakończony
-
Maureen LyonAmerican Cancer Society, Inc.ZakończonyNowotwórStany Zjednoczone
-
CIBA VISIONZakończony